jelmyto
Generic: mitomycin·Code: UGN-101
jelmyto: sourced relationships with 1 company · 1 FDA decision.
jelmyto evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect jelmyto to URGN; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could jelmyto → URGN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| UroGen Pharma Ltd. (URGN) | Approved |
FDA Decisions1 records
NDA211728Type 5 - New Formulation or New ManufacturerOrphan DrugPriorityOtherPowder
Frequently asked questions
Which companies have sourced relationships with jelmyto?
jelmyto has dated SEC/FDA relationship records for UroGen Pharma Ltd..
What is jelmyto's latest FDA decision?
The most recent tracked FDA decision for jelmyto is Approval for 1 INDICATIONS AND USAGE JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). JELMYTO is an alkylating drug indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). ( 1 ), dated April 15, 2020.